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Abstract
Breast cancer is the second leading cause of death among women in the
United States. Among the different molecular sub-groups of breast cancer, the
most invasive is Triple-Negative Breast Cancer (TNBC). TNBC has the worst
prognosis, decreased overall survival rate and no targeted therapy available.
On-going research is investigating new strategies and therapies for TNBC.
Therefore, this study’s objective was to compare and contrast the effects of
continuous low-dose of BIBR 1532, a novel analogue of BIBR1532 (GV6),
Paclitaxel and Doxorubicin on breast cancer (MDA-MB 231) cells. Culture flasks
(T-25) were seeded with approximately 5.0x105 cells/ml and supplemented with
GV6 (n=4-8) or BIBR 1532 (n=4-8) or Doxorubicin (n=4-8) or Paclitaxel (n=4-8)
or non-drug supplemented media (Control, n=4-8) for 21 days. Trypan Blue
(Gibco) exclusion test was utilized to assess the viability of the cells. BIBR 1532,
Doxorubicin and Paclitaxel reduced (P<0.05) proliferation of the cancer cells by
approximately 20-35% by day 7 of treatment compared to the Control. By day
21 of low-dose GV6, BIBR1532, Doxorubicin and Paclitaxel supplementation,
the cell counts dropped to about 25% (P<0.05), 55% (P<0.05), 75% (P<0.05)
and 50% (P<0.05) of Control, respectively. Our results indicate that continuous
low dose anti-telomerase and chemotherapeutic drugs do inhibit breast cancer
cell proliferation and merits further investigation.

Introduction
In 2014, the United States will have an estimated 250,000 new cases of
invasive breast cancer that accounts for 14% of all new cancer cases (1). Of the
250,000 new cases diagnosed in 2014, it is estimated that 40,000 will die due to
the disease, which accounts for about 7% of all cancer-related deaths (1). In
2012 there were 1.7 million new cases of breast cancer worldwide that cost
about $88 billion in health care (1). This number represented about 12% of all
new cancer cases and 25% of all cancers in women (9).
Breast cancers are currently classified into subclasses based on their
ultrastructural morphology. Among the most invasive, with high metastatic and
recurrence rates, as well as one of the worst prognoses is triple negative breast
cancer (TNBC). In the US, TNBC is occurring in higher rates in younger women
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and in African American women. The currently available drugs targeting other
subtypes that over express the estrogen receptor or progesterone receptor or
human epidermal growth factor receptor two (HER2) are of limited benefit with
TNBC. This type of cancer over time can become very aggressive and difficult to
treat. Due to the aggressive nature of TNBC, a higher dose of chemotherapy
and/or radiation is recommended to the patient. Studies have reported that
patients show a variety of adverse side effects with higher doses ranging from:
infertility, organ damage, secondary cancers, and fatality (1, 5, 6). For example,
when high dose of cyclophosphamide (180 mg/kg) is administered, 28% of
these patients start to show progressive signs of congestive heart failure, and
19% of these patients succumb due to cardiac failure (4).
Recent developments in life sciences are providing new understanding to
the cellular and molecular flaws of cancer cells. One field of study, being
pursued by cancer researchers is the regulation of cellular replication. The two
important elements of cellular replication are; division of the cytoplasm and the
duplication of DNA. The main focus of the scientist has been on DNA
replication, as it is part of the cell that encodes for all processes within the cell,
and is passed from one cell to another during cell division. Cancer emanates
when there is a flaw within one of the phases associated with DNA duplication,
therefore making the cancer cells divergent from normal cells. Cytoplasmic
replication has a limited role to play in triggering cancer because it is mostly
involved in transportation of intracellular components.
During DNA replication, the cell proceeds through an inherent systemic
quality control process via checkpoints, which detect alterations within the DNA.
The damage can be induced by the environment, chemicals or genetics.
Damaged or mutated cells cannot pass these checkpoints and are directed
towards senescence. These checkpoints are controlled by cyclins and if a cyclin
is mutated, it will affect the overall quality control process. Consequently, cancer
cells will be able to bypass these checkpoints with atypical cyclins without being
eliminated. Once these cells evade the internal screening mechanism, they
acquire unrestricted proliferative capacity leading to malignant cells (2). A
number of drugs targeting enzymes associated with the DNA duplication cycle
have been developed to halt progression of cancer cells. Among them is
Doxorubicin (DOX) from the anthracycline family, which is routinely used as an
anti-cancer drug. Doxorubicin inhibits enzymes, such as topoisomerase II that
are associated with DNA duplication.
In most human cells, an enzyme called telomerase helps cap the end of
chromosomal DNA (telomere), this activity is low and barely detectable. As the
DNA is replicated, telomere DNA becomes shorter with each cell division.
Ultimately, when the telomere becomes too short, the chromosomal DNA is not
protected and can be easily degraded (2). Interestingly now in cancer cells, we
know the telomerase is reactivated with each cell cycle, which lengthens the
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telomere to detectable lengths, causing the damaged DNA to stabilize and pass
through the cell division checkpoints (2). Further understanding, of the
telomere/telomerase complex has lead to the creation of a now common drug
called Azidothymidine (AZT). AZT was used extensively to treat HIV and AIDS
by targeting the replication of viral DNA. The knowledge of the
telomere/telomerase complex has lead to a development of other synthetic antitelomerase molecules, including BIBR1532 (3). BIBR 1532 blocks the limitless
proliferative capacity of metastatic cancerous cells by impeding the progression
of telomere/telomerase complex (2). A novel analogue of the BIBR1532, named
GV-6, has been developed at Grand Valley State University.

To counteract the side effects of the high-dose of chemotherapy used to
treat TNBC, a number of studies are investigating chronic low-dose therapies (5,
8, 9). Low dose therapies have been very effective at reducing the cytotoxic
effect of the chemotherapeutic agents (5, 8, 9). Overall, studies show that in a
low-dose therapy, the agent still has a significant effect on the cancerous cells,
such as tumor size, while demonstrating limited toxicity (5, 8, 9). A recent study
has shown that when a weekly low-dose was given, 36% of patients had a
progressive decrease in tumor sizes, while having a limited number of side
effects (5). The goal of this study was to evaluate the effect of chronic low-dose
mono-therapies (BIBR1532 or GV6 or DOX) compared to combination
(DOX+BIBR1532 or DOX+GV6) treatment on the proliferation of commercially
available TNBC (MDA-MB 231) cells.

Materials & Methods
a

R
NH
CH3

b

O

Cell line
Breast cancer cells (MDA-MB231) were cultured in
RPMI (Life Technologies, NY) media
supplemented with 10% fetal bovine serum
(Innovative Research, MI) plus 100uL of 100X
Anti-Anti (Life Technologies, NY) in an incubator
set at 37 °C and 5% CO2.

Treatment
Cells were seeded at a density of 0.50x106 cells/ml
Figure	
  1:	
  (a)	
  Chemical	
  structure	
  of	
  
(T25) and cultured for 72 hours in solvent-free
BIBR1532	
  (R=COOH)	
  and	
  GV6	
  
RPMI media to allow cells to acclimatize to culture
(R=unknown).	
  (b)	
  Chemical	
  structure	
  
of	
  Doxorubicin	
  
conditions. Thereafter, the media was switched to
	
  
fresh RPMI media alone for Control (n=2-4) or
media supplemented with 10µm GV6 (Fig 1), or 10µm BIBR1532 or 100nm DOX
(Fig 1) or 100nm DOX+10µm GV6 or 100nm DOX+10µm BIBR1532 (n=4-6).
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Viability Assessment
At days 7, 14, and 21 of culture with or without treatments, relative cell densities
were evaluated by using a hemocytometer and the live/dead ratios were
calculated using the Trypan Blue Exclusion Test (Life Technologies, NY). The
number of live/dead cells was estimated by counting and averaging the number
of cells within a set of four defined grids using an inverted microscope (Leica IL;
100X).
Senescence Test
A commercially available Senescence-Associated β-galactosidase (SA-βGal)
Staining Kit (Cell Signaling Technology, MA) was used on day 21 to detect the
cellular activity of β-galactosidase at an acidic pH. The average percentage of
SA-βGal positive cells per treatment was estimated from three independently
obtained micrographs using an inverted microscope (Olympus, PA; 100X)
a
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Figure 2: The Dose-Response curves of DOX,
Paclitaxel, BIBR1532 and GV6. Figure 3b DOX
and paclitaxel dose curve is made up of
concentrations from 10µM to 1nM. Figure 3a
BIBR1532 and GV6 dose curve is made up of
concentrations form 1mM to 1nM. The EC50 for
DOX, PAC, BIBR1532 and GV6 is: 201nM,
2
152nM, 15µM and 17µM, respectively. (R =0.98
to 0.99)

	
  

Statistical
Statistical analyses were performed
using the Student paired t-test. P <
0.05 was considered significant.

Dose Curve
The dose response curves of BIBR
1532, GV6, doxorubicin and paclitaxel
are shown in Figures 2a and b. There
was not a large difference in the EC50
concentrations of BIBR1532 and GV6
(201nM vs 152nM, respectively).
Similarly, the EC50 for doxorubicin was
comparable to that of paclitaxel (15µM
vs 17µM).The correlation coefficient
(R2) values for BIBR 1532, GV6, and
doxorubicin, paclitaxel dose-response
curves were 0.98 and 0.99,
respectively.
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Figure 3: Number of viable MDA-MB 231 cells in media supplemented with
GV6 and DOX+GV6 at days 7, 14, and 21 as determined by Trypan-Blue
exclusion test (n=4-6). Cells counts are expressed relative to Control. Data is
ac, and bd
shown as Mean ± SD;
means are significantly different (p<0.001).
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Figure 4:Number of viable MDA-MB 231 cells in media supplemented with
BIBR1532 and DOX+BIBR1532 at days 7, 14, and 21 as determined by
Trypan-Blue exclusion test (n=4-6). Cells counts are expressed relative to
ab
Control. Data is shown as Mean ± SD; means are significantly different
(p<0.001)	
  

21

Effects of Single and
Combination Antitelomerase and
Anthracycline therapy
on MDA-MB 231 cells
The Figures 3 and 4
show the effects of
single and combination
of anti-telomerase (GV6
or BIBR1532) and
anthracycline
(doxorubicin) therapy
on viable MDA-MB 231
cells for 7, 14 and 21
days compared to
Control.
The effects of the
combination of
doxorubicin with either
BIBR1532 or GV6
revealed a significant
effect (P<0.001)
compared to single
treatments. Both GV6
and BIBR1532 depicted
similar potencies when
compared to control.
The efficacy of the
combination treatment
increased with duration
of culture (p<0.001).

Senescence Test
No difference was noted between the number of active cells between single and
combination treatments (Figure 5a). The number of senescent cells was more in
single and combination treatments when compared to control (Figure 5b). The
amount of dead cells did not change much between treatments (Figure 6).

5	
  

	
  
Grand Valley State University
Effects of Chronic Low Dose Anti-Telomerase and
Chemotherapeutic Drugs on Breast Cancer Cells

	
  
Replicatively Active Cells

Active Cells (Percent of Control)

a
100

a

Control
GV6
BIBR1532
DOX+GV6
DOX+BIBR1532

80
60
40
20

b

c

0

b

e

1

Induction of Cell Senescence

600
Senescent	
  Cells	
  (Percent	
  of	
  Control)	
  
	
  

d

h
f

500

g

i

400
300
200
100

a
a

f

0
Figure	
  5:	
  Number	
  of	
  (A)	
  non-‐senescent	
  (replicatively	
  active)	
  cells,	
  and	
  
(B)	
  senescent	
  cell/treatment	
  in	
  comparison	
  to	
  Control	
  on	
  day	
  21	
  of	
  
treatment.	
  Data	
  is	
  shown	
  as	
  Mean	
  SD.	
  ab,	
  ad,	
  af,	
  ag,	
  ah,	
  and	
  a i	
  means	
  within	
  each	
  
panel	
  are	
  significantly	
  different	
  (p<0.05)	
  	
  

Discussion
TNBC has one the worst
prognosis because it is missing the
key factors that typical breast cancer
has (1). These key factors are the
reason why TNBC has one of the
poorest prognoses. With these
factors missing TNBC has a more
aggressive nature and is therefore
harder to treat. There is no specified
treatment for TNBC. The only current
treatment for TNBC is either a highdose of chemotherapy or radiation.
The high dose of these agents has
adverse side effects that can lead to
organ failure or even death (1,4,5,6).
Without a specific target to use
against TNBC, scientists have been
looking for other factors which can be
targeted to fight TNBC. A few of the
factors they have found that can be
targeted in TNBC cells are, the
amount of telomere DNA and the cell
checkpoints within the cell replication
stages. One of the most common
anthracycline is doxorubicin and the
most common anti-telomerase
agents is BIBR1532 and the novel
GV6 (2,3).	
  

Doxorubicin is noted to be
very effective against TNBC
(5,6,7,8). A recent study has shown that it reduces tumor size significantly but is
cytotoxic and cells do develop resistance (5,6,7,8). On other hand, BIBR1532 is
also shown to be very effective against TNBC. A recent study showed that
BIBR1532 worked very well against TNCB cells when glucose levels were
increased (13). The single and combination of effects of chronic low dose of
these chemotherapy drugs on MDA-MB 231 cells is the main target of this
study.
To our knowledge, this is the first study that demonstrates effectiveness
of BIBR1532 or GV6 in combination with DOX against TNBC in a chronic lowdose regime. The steady decrease in the number of viable MBA-MB 231 cells

6	
  

	
  
Grand Valley State University
Effects of Chronic Low Dose Anti-Telomerase and
Chemotherapeutic Drugs on Breast Cancer Cells

	
  
Number of Dead Cell within each Treatment
GV6
DOX
DOX+BIBR1532

Number of Dead Cells

30

BIBR1532
DOX+GV6

25
20
15
10
5
0
0

7

14

21

28

36

42

indicates that the treatments of
BIBR1532 or GV6 in combination with
DOX are efficacious (figure 3 and 4).
The results also show that the number
of senescent cells in the combination
trails have not increased when
compared to the single treatments
(figure 5). The amount of dead cells
within the combination trails also has
deceased slightly form the single
treatment trails. The results of this
experiment have shown that there is a
significant difference between single
and combination treatments.

Days of Treatment

The combination of the
BIBR1532 or GV6 with DOX shows
similar results (figure 3 and 4). Recent
studies have shown that the combination of different drugs with DOX when used
against TNBC has been more effective then single treatments with less cytotoxic
effects (5,8,9,10). A recent study revealed that the combination of doxorubicin or
paclitaxel with another anti-cancer or anti-telomerase drug is very effective
against many different cell lines (12). These results are very comparable to the
results shown here, presenting that both treatments works better in combination
versus single treatment.

Figure	
  6:	
  Number	
  of	
  dead	
  cells	
  per	
  treatment	
  over	
  a	
  42	
  day	
  period.	
  	
  

	
  

The dose curve for this trial showed an EC-50 of about 201nM for
doxorubicin. Another study has shown an EC-50 of 130 nM for doxorubicin (11).
This difference is plausibly from using two different cells lines and having slightly
different culture conditions between the two studies (11). Additionally, our study
found that the number of dead cells were generally higher in the single
treatments versus the combination treatments.
This preliminary study illustrates that the combination of anti-telomerase
with an anthracycline agents is more effective in inhibiting proliferation of TNBC
when compared to both single-drug anti-telomerase mono-therapies. Further
studies are necessary to verify and expand upon these current findings by next
using patient derived cells.
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